{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:31:19Z","timestamp":1791729079003,"version":"4.3.4"},"reference-count":26,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Purpose<\/jats:title><jats:p>The efficacy and safety of ravulizumab, a terminal complement C5 inhibitor, in adults with anti\u2010acetylcholine receptor antibody\u2010positive (AChR Ab+) generalized myasthenia gravis (gMG) were demonstrated in the CHAMPION MG study (NCT03920293). This analysis aimed to characterize the latency to onset of a clinically meaningful therapeutic effect for ravulizumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Post hoc analysis of data collected for up to 60\u2009weeks from CHAMPION MG was performed to assess the timing of response to ravulizumab. Response was analyzed based on reductions of \u22652 and \u22653 points (minimal clinically important differences [MCIDs]) in Myasthenia Gravis\u2013Activities of Daily Living (MG\u2010ADL) and Quantitative Myasthenia Gravis (QMG) total scores, respectively, and on more rigorous reductions of \u22653 and \u22655 points, respectively. Time to first response was assessed using the Kaplan\u2013Meier product\u2010limit method.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median (95% confidence interval) time to first response was 2.1 (2.1\u20132.6) and 4.1 (2.3\u201310.0) weeks for reductions of \u22652 and \u22653 points in MG\u2010ADL total score, respectively (<jats:italic>n<\/jats:italic>\u2009=\u2009139), and 4.1 (2.1\u201310.0) and 18.3 (11.0\u201333.4) weeks for reductions of \u22653 and \u22655 points in QMG total score, respectively (<jats:italic>n<\/jats:italic>\u2009=\u2009134). Cumulative response rates at Week 60 (data cut\u2010off) were 88% and 82% for \u22652\u2010 and \u22653\u2010point MG\u2010ADL score reductions, respectively, and 86% and 59% for \u22653\u2010 and \u22655\u2010point QMG score reductions, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The median times to MCID with ravulizumab treatment in patients with AChR Ab+ gMG were\u2009~2\u2009weeks and\u2009~4\u2009weeks based on MCID MG\u2010ADL and QMG total score reductions, respectively.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ene.16490","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T05:35:33Z","timestamp":1728279333000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Time to response with ravulizumab, a long\u2010acting terminal complement inhibitor, in adults with anti\u2010acetylcholine receptor antibody\u2010positive generalized myasthenia gravis"],"prefix":"10.1111","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3432-9747","authenticated-orcid":false,"given":"Ali A.","family":"Habib","sequence":"first","affiliation":[{"name":"University of California  Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Benatar","sequence":"additional","affiliation":[{"name":"Department of Neurology University of Miami Miller School of Medicine  Miami Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuan","family":"Vu","sequence":"additional","affiliation":[{"name":"Department of Neurology University of South Florida Morsani College of Medicine  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7233-5342","authenticated-orcid":false,"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[{"name":"Department of Neurology Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahram","family":"Attarian","sequence":"additional","affiliation":[{"name":"Reference Center for Neuromuscular Disorders and Amyotrophic Lateral Sclerosis, CHU La Timone Aix\u2010Marseille Universit\u00e9  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9453-9311","authenticated-orcid":false,"given":"Masahisa","family":"Katsuno","sequence":"additional","affiliation":[{"name":"Department of Neurology Nagoya University Graduate School of Medicine  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Liao","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen N.","family":"Beasley","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7136-8617","authenticated-orcid":false,"suffix":"Jr","given":"James F.","family":"Howard","sequence":"additional","affiliation":[{"name":"Department of Neurology The University of North Carolina  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,10,7]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2014.11.022"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13522"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S261414"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001169"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.8206.1"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-022-02493-6"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195909"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100066"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11699-x"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2012.06817.x"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23988"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.7.1487"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27476"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1998.tb11015.x"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.1.16"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51376"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00080-7"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-015-0398-y"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.12.003"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00028-0"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061597"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26910"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.5125"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000312374.95186.cc"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011108"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.16490","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T04:46:21Z","timestamp":1757565981000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.16490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,7]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1111\/ene.16490"],"URL":"https:\/\/doi.org\/10.1111\/ene.16490","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,7]]},"assertion":[{"value":"2024-05-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e16490"}}